---
title: "TriSalus Life Sciences - CW | 10-Q: FY2025 Q2 Revenue: USD 11.21 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252733638.md"
datetime: "2025-08-12T20:13:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252733638.md)
  - [en](https://longbridge.com/en/news/252733638.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252733638.md)
---

# TriSalus Life Sciences - CW | 10-Q: FY2025 Q2 Revenue: USD 11.21 M

Revenue: As of FY2025 Q2, the actual value is USD 11.21 M.

EPS: As of FY2025 Q2, the actual value is USD -0.27.

### Segment Revenue

-   **Revenue**: $11,213 for the three months ended June 30, 2025, compared to $7,364 for the same period in 2024, representing a 52.3% increase.

### Operational Metrics

-   **Gross Profit**: $9,411 for the three months ended June 30, 2025, compared to $6,452 for the same period in 2024, representing a 45.9% increase.
-   **Loss from Operations**: - $7,332 for the three months ended June 30, 2025, compared to - $8,174 for the same period in 2024.
-   **Net Loss**: - $8,288 for the three months ended June 30, 2025, compared to - $4,332 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $11,819 for the six months ended June 30, 2025, compared to - $24,289 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $30,405 for the six months ended June 30, 2025, compared to $29,119 for the same period in 2024.

### Unique Metrics

-   **Change in Fair Value of SEPA, Warrant, and Revenue Base Redemption Liabilities**: - $330 for the three months ended June 30, 2025, compared to - $9,016 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue the commercialization of TriNav and expand its market presence, leveraging new product launches such as TriNav LV and TriNav FLX to enhance therapeutic delivery capabilities.
-   **Non-Core Business**: The company is exploring partnerships for further development of nelitolimod, aiming to address barriers in the tumor microenvironment that inhibit the success of immunotherapy.
-   **Priority**: The company is focused on maintaining its current TriNav pricing and gross margins to support growth and R&D activities.

### Related Stocks

- [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md)

## Related News & Research

- [Oil drops on lower demand forecasts despite deadlock in US-Iran talks](https://longbridge.com/en/news/295727368.md)
- [Novo CEO says obesity market won't be winner-take-all battle with Lilly](https://longbridge.com/en/news/295777893.md)
- [Elon Musk's Tesla Weighs $10.1 Billion Solar Plant, Chamath Palihapitiya Calls It a Bet on Nuclear: Here's Why](https://longbridge.com/en/news/295754346.md)
- [Elon Musk Says AI Will Be SpaceX's Biggest Business by September: Does the Math Check Out?](https://longbridge.com/en/news/295681919.md)
- [CoreWeave and Nebius Group Deliver Earnings Shocker. Here's What It Signals About the Future of AI.](https://longbridge.com/en/news/295703122.md)